Welcome to our dedicated page for Genmab SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genmab’s antibody platforms power blockbuster drugs and an expansive oncology pipeline—but their SEC disclosures can stretch past 250 pages and dozens of exhibits. Finding where R&D spend shifts, or spotting when executives file Genmab insider trading Form 4 transactions, is challenging when every quarter brings new clinical data and collaboration milestones.
Stock Titan’s AI solves that problem. Our engine reads each Genmab quarterly earnings report 10-Q filing, highlights royalty streams from Darzalex and Tecvayli, and translates accounting footnotes into plain language. You’ll see
- Real-time alerts the moment a Genmab Form 4 insider transactions real-time record hits EDGAR.
- Concise explanations of 8-K material events—drug approvals, trial pauses, or amended AbbVie contracts—so Genmab 8-K material events explained makes sense in minutes.
- Side-by-side comparisons of cash burn across quarters to support your Genmab earnings report filing analysis.
Wondering about equity grants to management? The DEF 14A Genmab proxy statement executive compensation section is automatically summarised, while our dashboards track Genmab executive stock transactions Form 4 against upcoming catalyst dates. Need the big picture? Our AI creates a one-page brief titled Genmab annual report 10-K simplified so you can understand pipeline risks, patent cliffs, and royalty waterfalls without wading through technical jargon. For new investors asking, “How do I start understanding Genmab SEC documents with AI?”—this page is the starting point.
Royal Bank of Canada (RBC) is offering Market-Linked One Look Notes with Enhanced Buffer linked to the Class A common stock of Tesla, Inc. (TSLA). The notes are senior, unsecured debt securities that mature in approximately 14 months (September 2026) and are subject to RBC’s credit risk.
Key terms:
- Principal: $10 per unit; minimum purchase pricing to be set on the pricing date.
- Step Up Payment: between $3.00 and $3.60 per unit (30.00%–36.00%) if the Ending Value of TSLA is ≥ 85% of the Starting Value (the Threshold Value).
- Buffer: First 15% downside is absorbed; below the Threshold Value, investors lose principal on a 1-to-1 basis, exposing up to 85% of capital.
- No interim interest and no dividend participation.
- Credit & liquidity: Unsecured obligations of RBC; no FDIC/CDIC insurance; limited secondary market and no exchange listing.
- Fees: Public offering price $10.00; underwriting discount $0.175; hedging-related charge $0.05. For ≥300,000 units the price/discount improve to $9.95 and $0.125, respectively.
- Initial estimated value: $9.19–$9.69 per unit, below the public price, reflecting RBC’s internal funding rate and hedging costs.
Investors who believe TSLA will stay flat or rise above a 15% draw-down over the 14-month term can earn a fixed 30%–36% return. Conversely, a decline beyond 15% results in proportional losses, and a severe fall could result in an 85% maximum loss. All payments occur only at maturity, and repayment depends on RBC’s ability to pay.
Genmab A/S has filed a Form 6-K reporting transactions related to its ongoing share buy-back program for the period of June 16-20, 2025. The filing includes two key exhibits:
- A company announcement dated June 23, 2025, detailing transactions connected to the share buy-back program
- An appendix providing specific details of the share buyback program's execution for the week of June 16-20, 2025
The report was signed by Anthony Pagano, Executive Vice President & Chief Financial Officer. This Form 6-K will be incorporated by reference into Genmab's multiple S-8 registration statements (File Numbers: 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876). The company continues to file annual reports under Form 20-F as a foreign private issuer.
FAQ
What is the current stock price of Genmab (GMAB)?
What is the market cap of Genmab (GMAB)?
What is the primary focus of Genmab?
What proprietary technologies support Genmab's product portfolio?
How does Genmab generate revenue?
Which sectors does Genmab operate in?
Who are some of Genmab's key partners?
What competitive advantages does Genmab have?
How is Genmab positioned within the global biotech industry?
What areas of future research does Genmab focus on?
